NASDAQ
TFFP

Tff Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Tff Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$0.355
Today's High:
$0.385
Open Price:
$0.355
52W Low:
$0.32
52W High:
$6.05
Prev. Close:
$0.36
Volume:
30080

Company Statistics

Market Cap.:
$22.60 million
Book Value:
0.339
Revenue TTM:
$785146
Operating Margin TTM:
-3409.14%
Gross Profit TTM:
$-21212704
Profit Margin:
0%
Return on Assets TTM:
-80.66%
Return on Equity TTM:
-147.53%

Company Profile

Tff Pharmaceuticals Inc had its IPO on 2019-10-25 under the ticker symbol TFFP.

The company operates in the Healthcare sector and Biotechnology industry. Tff Pharmaceuticals Inc has a staff strength of 15 employees.

Stock update

Shares of Tff Pharmaceuticals Inc opened at $0.36 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.36 - $0.39, and closed at $0.37.

This is a +1.56% increase from the previous day's closing price.

A total volume of 30,080 shares were traded at the close of the day’s session.

In the last one week, shares of Tff Pharmaceuticals Inc have slipped by -4.29%.

Tff Pharmaceuticals Inc's Key Ratios

Tff Pharmaceuticals Inc has a market cap of $22.60 million, indicating a price to book ratio of 1.515 and a price to sales ratio of 133.4649.

In the last 12-months Tff Pharmaceuticals Inc’s revenue was $785146 with a gross profit of $-21212704 and an EBITDA of $-26298012. The EBITDA ratio measures Tff Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Tff Pharmaceuticals Inc’s operating margin was -3409.14% while its return on assets stood at -80.66% with a return of equity of -147.53%.

In Q2, Tff Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1090.4%.

Tff Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tff Pharmaceuticals Inc’s profitability.

Tff Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.4204. Its price to sales ratio in the trailing 12-months stood at 133.4649.

Tff Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$13.57 million
Total Liabilities
$1.21 million
Operating Cash Flow
$0
Capital Expenditure
$35709
Dividend Payout Ratio
0%

Tff Pharmaceuticals Inc ended 2024 with $13.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $13.57 million while shareholder equity stood at $12.28 million.

Tff Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $1.21 million in other current liabilities, 36193.00 in common stock, $-109159995.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.66 million and cash and short-term investments were $7.66 million. The company’s total short-term debt was $81,938 while long-term debt stood at $0.

Tff Pharmaceuticals Inc’s total current assets stands at $9.42 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $284169.00 compared to accounts payable of $1.01 million and inventory worth $0.

In 2024, Tff Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $35709.

Comparatively, Tff Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.37
52-Week High
$6.05
52-Week Low
$0.32
Analyst Target Price
$7.25

Tff Pharmaceuticals Inc stock is currently trading at $0.37 per share. It touched a 52-week high of $6.05 and a 52-week low of $6.05. Analysts tracking the stock have a 12-month average target price of $7.25.

Its 50-day moving average was $0.38 and 200-day moving average was $0.68 The short ratio stood at 0.23 indicating a short percent outstanding of 0%.

Around 1100.5% of the company’s stock are held by insiders while 1817.7% are held by institutions.

Frequently Asked Questions About Tff Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Tff Pharmaceuticals Inc is TFFP

The IPO of Tff Pharmaceuticals Inc took place on 2019-10-25

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$16.88
-1.47
-8.01%
Guess? Inc (GES)
$23.21
0.46
+2.02%
$48
1.1
+2.35%
$105.72
5.03
+5%
Tela Bio Inc (TELA)
$8.9
-0.02
-0.22%
$12.75
0.18
+1.43%
$0.12
-0
-3.15%
$2.51
-0.13
-4.92%
$0.15
-0
-0.07%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Address

1751 River Run, Austin, TX, United States, 76107